United States Federal Circuit

ResetAA Font size: Print

Shire Development, LLC v. Watson Pharms., Inc., 2016-1785

In a suit alleging defendant's infringement by filing an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration seeking to market a generic version of plaintiff's mesalamine drug, LIALDA, the district court's finding of infringement is reversed where defendant's ANDA product does not satisfy the Markush group requirements in claim 1(b).

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/02/10




  • United States Federal Circuit


FindLaw Career Center

      Post a Job  |  View More Jobs

    View More